Completed PHASE1 INTERVENTIONAL 4-arm NCT03796910

A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers

A Two-part, Randomized, Double-blind, Placebo-controlled, First-In-Human, Phase I Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 Following Administration of Single and Multiple Ascending Oral Doses in Healthy Volunteers

Sponsor: Simbec Research

Conditions Healthy Volunteers

Interventions Placebo for MAD Placebo for SAD SPR720 for MAD SPR720 for SAD

Updated 6 times since 2019 Last updated: Oct 24, 2019 Started: Dec 18, 2018 Primary completion: Sep 24, 2019 Completion: Sep 24, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03796910, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by Simbec Research, it has been updated 6 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Nov 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 1 earlier version

Feb 2019 — Nov 2019 [monthly]

Recruiting PHASE1

First recorded

Dec 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Simbec Research
Spero Therapeutics

Data source: Spero Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Merthyr Tydfil, United Kingdom